Shots:

• The NMPA has accepted the NDA for CAN108 for cholestatic pruritus in patients aged ≥1yr. with ALGS. Additionally, priority review is expected to be granted, upon closure of the priority review process
• CANbridge entered into an exclusive license agreement with Mirum to develop & commercialize maralixibat in Greater China where CANbridge obtains the right to develop & commercialize CAN108 for 3 indications: ALGS, PFIC & BA in Greater China
• Livmarli is an IBAT inhibitor & is 1st FDA-approved therapy for cholestatic pruritus associated with ALGS. The therapy is being evaluated in a P-III trial for PFIC in North America, EU, Asia, & South America while P-IIb (EMBARK) trial for BA is underway

Ref: Businesswire | Image: Businesswire